AUTHORS
Marisa J L Aitken, MD, PhD, Rachel M Fanous, BS2, Reid Williams, BS3, Zachary S Wilson, PhD4, Nicholas Armas, BS5, Alexander T Dils, MD6, Kantaro Inoki7, Luis O Correa-Medero, PhD8, Shannon Carty, MD9
AFFILIATIONS
1 University of Michigan, Ann Arbor, Michigan, United States
2 University of Michigan, Ann Arbor, Michigan, United States
3 University of Michigan, Ann Arbor, Michigan, United States
4 University of Michigan, Ann Arbor, Michigan, United States
5 University of Michigan, Ann Arbor, Michigan, United States
6 University of Michigan, Ann Arbor, Michigan, United States
7 University of Michigan, Ann Arbor, Michigan, United States
8 Broad Institute of MIT & Harvard, Cambridge, Massachusetts, United States
9 University of Michigan, Ann Arbor, Michigan, United States
ABSTRACT
CD8+ T cells are the primary effectors of anti-tumor and anti-viral immunity and serve as backbones of most cancer immunotherapies, including checkpoint inhibitors, chimeric antigen receptor (CAR)-T cells, and bispecific antibodies. While clinically transformative, these therapies lack universal clinical responses. Better understanding of fundamental T cell biology may help address this limitation.
Following antigen encounter, CD8+ T cells undergo rapid clonal expansion, demanding robust metabolic reprogramming predicated on adequate nutrient availability. Lysosomes are central to this process. Beyond degrading macromolecules to generate metabolic building blocks, lysosomes sense amino acid abundance and serve as signaling platforms. While the importance of lysosomes in CD8+ T cell cytotoxic effector function is well established—lytic granules (specialized secretory lysosomes) harbor granzyme and perforin—their roles in earlier phases of T cell activation and clonal expansion have not been described. Given the central role of lysosomes in cellular metabolism, we evaluated lysosome biogenesis and consequences of its disruption early in CD8+ T cell activation.
We find that human and mouse CD8+ T cells increase lysosomal mass within 24 hours of activation in vitro, continuing over several days and preceding acquisition of effector function. Lysosome proteolytic activity also increases during this timeframe. This biogenesis occurs under T cell receptor-mediated activation conditions, including with the CD3/CD20 bispecific antibody mosunetuzumab, highlighting relevance to T cell-directed immunotherapies.
Concordantly, activated CD8+ T cells upregulate transcription factor EB (TFEB), a master regulator of lysosome biogenesis. To disrupt this process, we used T cell-specific conditional TFEB knockout mice (Tfebfl/flCD4Cre; TfebKO). At baseline, TfebKO mice have normal quantities and phenotypes of CD4+ and CD8+ T cells with similar basal lysosome levels. To assess consequences of disrupted lysosome biogenesis following antigen challenge, we co-transferred virus-specific CD8+ T cells from control and TfebKO mice (1:1) into congenic wildtype recipients and infected with lymphocytic choriomeningitis virus (LCMV). As early as day 3 post-infection, control T cells predominated in spleen and lymph nodes (LN: 69.3% vs 30.7%, p<0.0001). TfebKO T cells remained viable but exhibited a marked proliferative disadvantage. By day 8, corresponding with peak CD8+ T cell response, TfebKO cells comprised minimal percentages of LCMV-specific T cells across all tissues examined, including spleen, lymph nodes, blood, liver, and small intestine (LN: 99.45% vs 0.49%, p<0.0001), arguing against a homing defect. Lysosomal mass remained diminished in TfebKO cells at both timepoints. This proliferative defect was confirmed in single-transfer experiments, excluding cellular competition as the primary explanation. Cell surface activation marker expression was consistently diminished in TfebKO T cells, suggesting that defective lysosome biogenesis impairs CD8+ T cell activation and subsequent proliferation.
To determine whether TfebKO T cells could divide under non-antigen-driven stimulation, we co-transferred TfebKO and control CD8+ T cells into lymphopenic recipient mice (Rag2-/-). TfebKO cells proliferated akin to controls (LN: 50.1% vs 49.7%), indicating the defect is specific to antigen-driven expansion.
Remarkably, in vitro culture conditions fully rescue TfebKO proliferative defects. TfebKO cells activate, proliferate, and form lysosomes indistinguishably from controls across multiple activation methods, competitive and non-competitive settings, and physiologic (human plasma-like) media. However, co-transfer of in vitro-activated LCMV-specific TfebKO and control T cells into LCMV-infected recipients re-demonstrates a profound proliferative deficit. Together, these data establish that TFEB-mediated lysosome biogenesis is required for antigen-driven CD8+ T cell expansion in vivo and underscore the microenvironmental dependence of this requirement.
Ongoing work evaluates the metabolic consequences of disrupted lysosome biology in CD8+ T cells. Single-cell RNA sequencing of LCMV-specific T cells from control and TfebKO donors following LCMV will be presented at the annual meeting. Further studies are assessing the role of lysosome biogenesis in B-cell lymphoma tumor models, where bispecific antibodies and CAR-T cells are therapeutic mainstays.
DISCLOSURES
Marisa J L Aitken, MD, PhD: No relevant conflicts of interest to declare.